Polymun

The core competence of Polymun is the development and manufacture of biopharmaceuticals, using both mammalian mammalian and microbial cell technology. A fine example are Polymun′s broadly neutralizing HIV-1 antibodies produced in CHO cells. Another example is the recombinant human trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.

Polymun employs a team of about 40 dynamic and highly qualified scientists, technologists and support staff. The average age is 34, and 60% hold an academic title, mostly in natural sciences such as biotechnology, biology or chemistry. About one third have graduated at technical schools or colleges. Men and women are found equally in all positions. Polymun is also giving several of its employees the opportunity to perform their master or doctor theses within the scope of the company. With quality and reliability as a pre-requisite basis, innovation and creativity are strongly encouraged at Polymun.

Located within the campus of the University of Natural Resources and Applied Life Sciences, Polymun has close contacts to the Institute of Applied Microbiology (IAM). The fruitful scientific dialog and the broad methodological competence is of mutual benefit.
Polymun is partner in six projects of the EU 6th Framework Programme (PHARMA-PLANTA, HIV VIROSOMES, EPI-VAC, HIVAB, EMPRO, and EUROPRISE). Furthermore, Polymun is active in two projects of the Grand Challenges in Global Health sponsored by the Bill & Melinda Gates Foundation and the Wellcome Trust. Polymun is part of the competence center of BioMolecular Therapeutics (BMT).